Myocardial Infarction
Recent clinical, regulatory, research and industry developments relating to this disease.
Neuroinflammation After Myocardial Infarction - Imaging Substudy
CHMP positive opinion: Colchicine Agepha Pharma (EMA)
Market withdrawal: Integrilin (EMA)
Skeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes.
T cells in cardiac health and disease.
Sudden cardiac death after myocardial infarction: individual participant data from pooled cohorts.
Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial.
Microplastics and Nanoplastics in Atheromas and Cardiovascular Events.
Market withdrawal: Rapilysin (EMA)
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 5 clinical trials expected to report results, the earliest in Q4 2026.
- 1 industry development reported.
- Q4 2026Non-commercial Clinical Trial of Statins CAncer Preventive and Pleiotropic TherApy IN Smokers With Chronic Obstructive Pulmonary Disease (COPD)
- Q1 2027ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial Infarction
- Q1 2027Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy. A 2x2 Factorial, All-comer, Multicenter, Randomized Controlled Trial: ANGIODAPT
- Q2 2027Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine
- Q4 2027A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/Ezetimibe Fixed Dose Combination Daily on Coronary Plaque Characteristics in Participants With Atherosclerotic Cardiovascular Disease on Coronary CT Angiography (REMBRANDT Trial)
Clinical MilestonesView all 9Hide
- 2026-09-09ARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial InfarctionResults expected Q1 2027
- 2026-06-12Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and ColchicineResults expected Q2 2027
- 2026-05-15Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy. A 2x2 Factorial, All-comer, Multicenter, Randomized Controlled Trial: ANGIODAPTResults expected Q1 2027
- 2026-04-21Non-commercial Clinical Trial of Statins CAncer Preventive and Pleiotropic TherApy IN Smokers With Chronic Obstructive Pulmonary Disease (COPD)Results expected Q4 2026
- 2026-04-09A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/Ezetimibe Fixed Dose Combination Daily on Coronary Plaque Characteristics in Participants With Atherosclerotic Cardiovascular Disease on Coronary CT Angiography (REMBRANDT Trial)Results expected Q4 2027
- 2030-12-01A Multicenter, Randomized, Outcomes Assessor Blind, Parallel Controlled Trial to Evaluate the Effect of Oral Isosorbide Mononitrate Plus Amlodipine Antispasm Therapy on Outcomes of Radial Artery Grafts After Coronary Artery Bypass GraftingWithdrawn
- 2026-05-16Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (EVALUATE-STEMI Trial): a Prospective, Multicenter, Open-label, Adjudicator-blinded, Randomized Clinical TrialTerminated
- 2026-02-26Personalization of Long-Term Antiplatelet Therapy Using a Novel Combined Demographic/Pharmacogenomic Strategy - The RAPID EXTEND Randomized StudyTerminated
Industry & MarketViewHide
- 2026-10-22Sepsis Prior to Total Knee Arthroplasty is Associated With Elevated Rates of Myocardial Infarction and Deep Vein ThrombosisIndustry · The Journal of Arthroplasty
Regulatory UpdatesViewHide
- 2026-05-22CHMP positive opinion — ColchicineIndicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in patients with atherosclerotic disease or with multiple risk factors for cardiovascular disease.
- 2026-01-01Product authorisation ended — EptifibatideIntegrilin is intended for use with acetylsalicylic acid and unfractionated heparin. Integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-Q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ECG changes and / or elevated cardiac enzymes. Patients most likely to benefit from Integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (PTCA).
- 2030-12-01ClinicalA Multicenter, Randomized, Outcomes Assessor Blind, Parallel Controlled Trial to Evaluate the Effect of Oral Isosorbide Mononitrate Plus Amlodipine Antispasm Therapy on Outcomes of Radial Artery Grafts After Coronary Artery Bypass GraftingWithdrawn
- 2026-10-22IndustrySepsis Prior to Total Knee Arthroplasty is Associated With Elevated Rates of Myocardial Infarction and Deep Vein ThrombosisIndustry · The Journal of Arthroplasty
- 2026-09-09ClinicalARTEMIS - Effects of Ziltivekimab Versus Placebo on Cardiovascular Outcomes in Patients With Acute Myocardial InfarctionResults expected Q1 2027
- 2026-08-05ClinicalVerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA Trial)Completed
- 2026-06-12ClinicalPolygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and ColchicineResults expected Q2 2027
- 2026-05-22RegulatoryCHMP positive opinion — ColchicineIndicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in patients with atherosclerotic disease or with multiple risk factors for cardiovascular disease.
- 2026-05-16ClinicalEffect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (EVALUATE-STEMI Trial): a Prospective, Multicenter, Open-label, Adjudicator-blinded, Randomized Clinical TrialTerminated
- 2026-05-15ClinicalIschemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy. A 2x2 Factorial, All-comer, Multicenter, Randomized Controlled Trial: ANGIODAPTResults expected Q1 2027
- 2026-04-21ClinicalNon-commercial Clinical Trial of Statins CAncer Preventive and Pleiotropic TherApy IN Smokers With Chronic Obstructive Pulmonary Disease (COPD)Results expected Q4 2026
- 2026-04-09ClinicalA Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/Ezetimibe Fixed Dose Combination Daily on Coronary Plaque Characteristics in Participants With Atherosclerotic Cardiovascular Disease on Coronary CT Angiography (REMBRANDT Trial)Results expected Q4 2027
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Product authorisation ended — Integrilin is intended for use with acetylsalicylic acid and unfractionated heparin. Inte… (2026)
Product authorisation ended — Rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction… (2024)
Generic approval — Prasugrel Viatris, co administered with acetylsalicylic acid (ASA), is indicated for the… (2018)
Biosimilar approval — Inhixa is indicated for adults for: Prophylaxis of venous thromboembolism, particularly… (2016)
Generic approval — Secondary prevention of atherothrombotic events Clopidogrel is indicated in: Adult patie… (2015)
Original application approval — Hypercholesterolaemia and mixed dyslipidaemia Repatha is indicated in adults with primary… (2015)
Original application approval — Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the preventio… (2010)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Myocardial Infarction23
- Cardiovascular Diseases6
- Coronary Artery Disease6
- Percutaneous Coronary Intervention5
- Stroke5
- Cardiac Rehabilitation4
- Heart Failure4
- Computed Tomography Angiography3
Leading journals6
- The New England journal of medicine19
- European heart journal13
- Circulation9
- The Journal of clinical investigation3
- Cardiovascular diabetology2
- JAMA2
Leading researchers8
- Califf RM4
- Hochman JS4
- Pfeffer MA4
- Smith SC Jr4
- Solomon SD4
- Braunwald E3
- Jacobs AK3
- Krumholz HM3
Affiliations (unnormalised)6
- Brigham and Women's Hospital9
- Duke Clinical Research Institute3
- Brigham and Women's Hospital and Harvard Medical School2
- Lerner Research Institute2
- Odense University Hospital2
- Royal Papworth Hospital2
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Myocardial infarction is necrosis of the heart muscle caused by obstruction of the coronary blood supply. It is a major cause of death and disability worldwide and is commonly discussed in relation to acute ischemic injury, diagnosis, complications, and mortality.
The immediate cause is obstruction of the coronary circulation leading to myocardial ischemia and necrosis. The grounding also supports atherosclerotic risk management and blood pressure-related cardiovascular prevention as relevant to myocardial infarction, but it does not provide a more specific causal chain beyond coronary obstruction.
Reduced coronary blood flow causes myocardial ischemia and cell death, with reperfusion able to limit infarct size but also to trigger reperfusion injury. Necrosis activates complement, free radical generation, and a cytokine cascade involving TNF-alpha, IL-8, C5a, and neutrophil recruitment, contributing to inflammatory injury and repair. Post-infarction remodeling of cardiac structure and function is also a major downstream process.
The grounding supports high cardiovascular risk status, diabetes, and blood pressure as relevant factors in myocardial infarction prevention and outcomes. It also supports lipid-related risk management, including LDL cholesterol and HDL cholesterol, and mentions glycated hemoglobin as a co-studied marker. Additional risk factors are not explicitly supported in the supplied material.
Acute myocardial infarction is generally treated with timely reperfusion, using thrombolytic therapy or primary percutaneous coronary intervention. Secondary prevention and risk reduction include therapeutic lifestyle changes, statin-based cholesterol lowering, and pharmacological blood pressure lowering in appropriate cardiovascular-risk settings. The grounding also supports use of ACE inhibitor and angiotensin receptor blocker drug classes as co-studied therapies, but it does not provide specific regimens.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.